Skip to main content

MECANISMOS MOLECULARES DE PROGRESION TUMORAL EN MODELOS DE NEOPLASIAS INICIADAS POR PERDIDA DE PTEN

SAF2016-80157-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2016
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDAD DE LLEIDA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Repositori Obert UdL
Publication Artículo científico (JournalArticle)

Palbociclib has antitumour effects on Pten-deficient endometrial neoplasias, Inhibition of Cyclin D-CDK4/6 axis in PTEN-deficient neoplasias

  • Dosil Garcia, Maria Alba
  • Mirantes Barbeito, Cristina
  • Eritja Sánchez, Núria
  • Felip Nogués, Isidre
  • Navaridas Fernández de Bobadilla, Raúl
  • Gatius Calderó, Sònia
  • Santacana Espasa, Maria
  • Colás, Eva
  • Moiola, Cristian P.
  • Schoenenberger, Joan Antoni
  • Encinas Martín, Mario
  • Garí Marsol, Eloi
  • Matias-Guiu, Xavier
  • Dolcet Roca, Xavier
PTEN is one of the most frequently mutated genes in human cancers. The frequency of PTEN alterations is particularly high in endometrial carcinomas. Loss of PTEN leads to dysregulation of cell division, and promotes the accumulation of cell cycle complexes such as cyclin D1-CDK4/6, which is an important feature of the tumour phenotype. Cell cycle proteins have been presented as key targets in the treatment of the pathogenesis of cancer, and several CDK inhibitors have been developed as a strategy to generate new anticancer drugs. Palbociclib (PD-332991) specifically inhibits CDK4/6, and it has been approved for use in metastatic breast cancer in combination with letrazole. Here, we used a tamoxifen-inducible Pten knockout mouse model to assess the antitumour effects of cyclin D1 knockout and CDK4/6 inhibition by palbociclib on endometrial tumours. Interestingly, both cyclin D1 deficiency and palbociclib treatment triggered shrinkage of endometrial neoplasias. In addition, palbociclib treatment significantly increased the survival of Pten-deficient mice, and, as expected, had a general effect in reducing tumour cell proliferation. To further analyse the effects of palbociclib on endometrial carcinoma, we established subcutaneous tumours with human endometrial cancer cell lines and primary endometrial cancer xenografts, which allowed us to provide more translational and predictive data. To date, this is the first preclinical study evaluating the response to CDK4/6 inhibition in endometrial malignancies driven by PTEN deficiency, and it reveals an important role of cyclin D-CDK4/6 activity in their development., This work was supported by grants FIS PI13/00263, SAF2016-80157-R, PI13/01701, 2009SGR794,Grupos estables AECC (AECC2011), RETICS(RD12/0036/0013), Catalunya contra el cáncer, Programa de intensificación de la investigación, Instituto Carlos III, and BFU 2013-42895-P. MAD holds a predoctoral fellowship from Ministerio de Educación
Repositori Obert UdL
Publication Artículo científico (JournalArticle)

Endometrial PTEN Deficiency Leads to SMAD2/3 Nuclear Translocation

  • Eritja Sánchez, Núria
  • Navaridas Fernández de Bobadilla, Raúl
  • Ruiz Mitjana, Anna
  • Vidal Sabanés, Maria
  • Egea Navarro, Joaquim
  • Encinas Martín, Mario
  • Matias-Guiu, Xavier
  • Dolcet Roca, Xavier
TGF-β has a dichotomous function, acting as tumor suppressor in premalignant cells but as a tumor promoter for cancerous cells. These contradictory functions of TGF-β are caused by different cellular contexts, including both intracellular and environmental determinants. The TGF-β/SMAD and the PI3K/PTEN/AKT signal transduction pathways have an important role in the regulation of epithelial cell homeostasis and perturbations in either of these two pathways' contributions to endometrial carcinogenesis. We have previously demonstrated that both PTEN and SMAD2/3 display tumor-suppressive functions in the endometrium, and genetic ablation of either gene results in sustained activation of PI3K/AKT signaling that suppresses TGF-β-induced apoptosis and enhances cell proliferation of mouse endometrial cells. However, the molecular and cellular effects of PTEN deficiency on TGF-β/SMAD2/3 signaling remain controversial. Here, using an in vitro and in vivo model of endometrial carcinogenesis, we have demonstrated that loss of PTEN leads to a constitutive SMAD2/3 nuclear translocation. To ascertain the function of nuclear SMAD2/3 downstream of PTEN deficiency, we analyzed the effects of double deletion PTEN and SMAD2/3 in mouse endometrial organoids. Double PTEN/SMAD2/3 ablation results in a further increase of cell proliferation and enlarged endometrial organoids compared to those harboring single PTEN, suggesting that nuclear translocation of SMAD2/3 constrains tumorigenesis induced by PTEN deficiency., This research was supported by grants SAF2016-80157-R and PID2019-104734RB-I00 from Spanish Ministerio de Ciencia, Innovación y Universidades, Grupos estables de la Asociación Española Contra el Cancer, AECC
Repositori Obert UdL
Publication Artículo científico (JournalArticle)

ENDOG Impacts on Tumor Cell Proliferation and Tumor Prognosis in the Context of PI3K/PTEN Pathway Status

  • Barés Junqué, Gisel
  • Beà Tàrrega, Aida
  • Hernández, Luís
  • Navaridas Fernández de Bobadilla, Raúl
  • Felip Nogués, Isidre
  • Megino-Luque, Cristina
  • Blasco Angulo, Natividad
  • Nadeu, Ferran
  • Campo, Elías
  • Llovera i Tomàs, Marta
  • Dolcet Roca, Xavier
  • Sanchis, Daniel
EndoG influences mitochondrial DNA replication and is involved in somatic cell proliferation. Here, we investigated the effect of ENDOG/Endog expression on proliferation in different tumor models. Noteworthy, ENDOG deficiency reduced proliferation of endometrial tumor cells expressing low PTEN/high p-AKT levels, and Endog deletion blunted the growth of PTEN-deficient 3D endometrial cultures. Furthermore, ENDOG silencing reduced proliferation of follicular thyroid carcinoma and glioblastoma cell lines with high p-AKT expression. High ENDOG expression was associated with a short time to treatment in a cohort of patients with chronic lymphocytic leukemia (CLL), a B-cell lymphoid neoplasm with activation of PI3K/AKT. This clinical impact was observed in the less aggressive CLL subtype with mutated IGHV in which high ENDOG and low PTEN levels were associated with worse outcome. In summary, our results show that reducing ENDOG expression hinders growth of some tumors characterized by low PTEN activity and high p-AKT expression and that ENDOG has prognostic value for some cancer types., This research was funded by Ministerio de Ciencia, Innovación y Universidades, Gobierno de España, grant numbers SAF2013-44942-R and PID2019-104509RB-I00 to D.S.; grant numbers SAF2016-80157-R and PID2019-104734RB-I00 to X.D.; Fundació La Marató TV3, grant number 20153810 to D.S. G.B. holds a contract from the University of Lleida; A.B. holds a contract from Fundació La Marató TV3 and IRBLleida/Diputació de Lleida; The Spanish Ministry of Science and Innovation (MICINN) through the Instituto de Salud Carlos III (ISCIII) International Cancer Genome Consortium for Chronic Lymphocytic Leukemia (ICGC-CLL Genome Project) to E.C.. Fundació La Marato de TV3 (201920-30) to L.H. Support Groups de Recerca AGAUR 2014-SGR-795 of the Generalitat de Catalunya to E.C.
Repositori Obert UdL
Publication Artículo científico (JournalArticle)

A Smad3-PTEN regulatory loop controls proliferation and apoptotic responses to TGF-β in mouse endometrium, SMAD3-PTEN crosstalk regulates TGF-β responses

  • Eritja Sánchez, Núria
  • Felip Nogués, Isidre
  • Dosil Garcia, Maria Alba
  • Vigezzi, Lucia
  • Mirantes Barbeito, Cristina
  • Yeramian Hakim, Andree
  • Navaridas Fernández de Bobadilla, Raúl
  • Santacana Espasa, Maria
  • Llobet Navàs, David
  • Yoshimura, Akihiko
  • Nomura, Masatoshi
  • Encinas Martín, Mario
  • Matias-Guiu, Xavier
  • Dolcet Roca, Xavier
The TGF-β/Smad and the PI3K/AKT signaling pathways are important regulators of proliferation and apoptosis, and their alterations lead to cancer development. TGF-β acts as a tumor suppressor in premalignant cells, but it is a tumor promoter for cancerous cells. Such dichotomous actions are dictated by different cellular contexts. Here, we have unveiled a PTEN-Smad3 regulatory loop that provides a new insight in the complex cross talk between TGF-β/Smad and PI3K/AKT signaling pathways. We demonstrate that TGF-β triggers apoptosis of wild-type polarized endometrial epithelial cells by a Smad3-dependent activation of PTEN transcription, which results in the inhibition of PI3K/AKT signaling pathway. We show that specific Smad3 knockdown or knockout reduces basal and TGF-β-induced PTEN expression in endometrial cells, resulting in a blockade of TGF-β-induced apoptosis and an enhancement of cell proliferation. Likewise Smad3 deletion, PTEN knockout prevents TGF-β-induced apoptosis and increases cell proliferation by increasing PI3K/AKT/mTOR signaling. In summary, our results demonstrate that Smad3-PTEN signaling axis determine cellular responses to TGF-β., Supported by grants SAF2016-80157-R from Ministerio de Economía y Competitividad, PI13/00263 and PI13/01701 from Fondo de Investigaciones Sanitarias del Instituto de Salud Carlos III cofinanciado por Fondo Europeo de Desarrollo Regional (FEDER) (“Una manera de hacer Europa”), Red Temática de investigación en Cáncer RD12/0036/0013 and Red de Oncología (CIBERONC). Grups consolidats de la Generalitat de Catalunya (2009SGR794), Fundació La Marató de TV3, Grupos estables AECC, Catalunya contra el cáncer and programa de intensificación de la investigación, Instituto Carlos III.
Repositori Obert UdL
Publication Artículo científico (JournalArticle)

Involvement of the mitochondrial nuclease EndoG in the regulation of cell proliferation through the control of reactive oxygen species

  • Blasco Angulo, Natividad
  • Beà Tàrrega, Aida
  • Barés Junqué, Gisel
  • Girón, Cristina
  • Navaridas Fernández de Bobadilla, Raúl
  • Irazoki, Andrea
  • López-Lluch, Guillermo
  • Zorzano, Antonio
  • Dolcet Roca, Xavier
  • Llovera i Tomàs, Marta
  • Sanchis, Daniel
The apoptotic nuclease EndoG is involved in mitochondrial DNA replication. Previous results suggested that, in addition to regulate cardiomyocyte hypertrophy, EndoG could be involved in cell proliferation. Here, by using in vivo and cell culture models, we investigated the role of EndoG in cell proliferation. Genetic deletion of Endog both in vivo and in cultured cells or Endog silencing in vitro induced a defect in rodent and human cell proliferation with a tendency of cells to accumulate in the G1 phase of cell cycle and increased reactive oxygen species (ROS) production. The defect in cell proliferation occurred with a decrease in the activity of the AKT/PKB-GSK-3β-Cyclin D axis and was reversed by addition of ROS scavengers. EndoG deficiency did not affect the expression of ROS detoxifying enzymes, nor the expression of the electron transport chain complexes and oxygen consumption rate. Addition of the micropeptide Humanin to EndoG-deficient cells restored AKT phosphorylation and proliferation without lowering ROS levels. Thus, our results show that EndoG is important for cell proliferation through the control of ROS and that Humanin can restore cell division in EndoG-deficient cells and counteracts the effects of ROS on AKT phosphorylation., This research was funded by Ministerio de Ciencia e Innovación, Gobierno de España, grant numbers SAF2013-44942-R and PID2019-104509RB-I00 to D.S. and SAF2016-80157-R to X.D.; Fundació La Marató, Catalunya, grant number 20153810 to D.S.; AGAUR, Generalitat de Catalunya, Catalunya, grant number 2014-SGR-1609 to D.S. G.B. holds a contract from the University of Lleida; A.B. contract has been funded by Fundació La Marató TV3 and Diputació de Lleida/IRBLleida.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Involvement of the mitochondrial nuclease EndoG in the regulation of cell proliferation through the control of reactive oxygen species

  • Blasco, Natividad
  • Beà, Aida
  • Barés, Gisel
  • Girón, Cristina
  • Navaridas, Raúl
  • Irazoki, Andrea
  • López-Lluch, Guillermo
  • Zorzano, Antonio
  • Dolcet, Xavier
  • Llovera, Marta
  • Sanchis, Daniel
© 2020 The Author(s)., The apoptotic nuclease EndoG is involved in mitochondrial DNA replication. Previous results suggested that, in addition to regulate cardiomyocyte hypertrophy, EndoG could be involved in cell proliferation. Here, by using in vivo and cell culture models, we investigated the role of EndoG in cell proliferation. Genetic deletion of Endog both in vivo and in cultured cells or Endog silencing in vitro induced a defect in rodent and human cell proliferation with a tendency of cells to accumulate in the G1 phase of cell cycle and increased reactive oxygen species (ROS) production. The defect in cell proliferation occurred with a decrease in the activity of the AKT/PKB-GSK-3β-Cyclin D axis and was reversed by addition of ROS scavengers. EndoG deficiency did not affect the expression of ROS detoxifying enzymes, nor the expression of the electron transport chain complexes and oxygen consumption rate. Addition of the micropeptide Humanin to EndoG-deficient cells restored AKT phosphorylation and proliferation without lowering ROS levels. Thus, our results show that EndoG is important for cell proliferation through the control of ROS and that Humanin can restore cell division in EndoG-deficient cells and counteracts the effects of ROS on AKT phosphorylation., This research was funded by Ministerio de Ciencia e Innovación, Gobierno de España, grant numbers SAF2013-44942-R and PID2019-104509RB-I00 to D.S. and SAF2016-80157-R to X.D.; Fundació La Marató, Catalunya, grant number 20153810 to D.S.; AGAUR, Generalitat de Catalunya, Catalunya, grant number 2014-SGR-1609 to D.S. G.B. holds a contract from the University of Lleida; A.B. contract has been funded by Fundació La Marató TV3 and Diputació de Lleida/IRBLleida.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Palbociclib has antitumour effects on Pten-deficient endometrial neoplasias, Inhibition of Cyclin D-CDK4/6 axis in PTEN-deficient neoplasias

  • Dosil Garcia, Maria Alba
  • Mirantes Barbeito, Cristina
  • Eritja Sánchez, Núria
  • Felip Nogués, Isidre
  • Navaridas Fernández de Bobadilla, Raúl
  • Gatius Calderó, Sònia
  • Santacana Espasa, Maria
  • Colás, Eva
  • Moiola, Cristian P.
  • Schoenenberger, Joan Antoni
  • Encinas Martín, Mario
  • Garí Marsol, Eloi
  • Matias-Guiu, Xavier
  • Dolcet Roca, Xavier
PTEN is one of the most frequently mutated genes in human cancers. The frequency of PTEN alterations is particularly high in endometrial carcinomas. Loss of PTEN leads to dysregulation of cell division, and promotes the accumulation of cell cycle complexes such as cyclin D1-CDK4/6, which is an important feature of the tumour phenotype. Cell cycle proteins have been presented as key targets in the treatment of the pathogenesis of cancer, and several CDK inhibitors have been developed as a strategy to generate new anticancer drugs. Palbociclib (PD-332991) specifically inhibits CDK4/6, and it has been approved for use in metastatic breast cancer in combination with letrazole. Here, we used a tamoxifen-inducible Pten knockout mouse model to assess the antitumour effects of cyclin D1 knockout and CDK4/6 inhibition by palbociclib on endometrial tumours. Interestingly, both cyclin D1 deficiency and palbociclib treatment triggered shrinkage of endometrial neoplasias. In addition, palbociclib treatment significantly increased the survival of Pten-deficient mice, and, as expected, had a general effect in reducing tumour cell proliferation. To further analyse the effects of palbociclib on endometrial carcinoma, we established subcutaneous tumours with human endometrial cancer cell lines and primary endometrial cancer xenografts, which allowed us to provide more translational and predictive data. To date, this is the first preclinical study evaluating the response to CDK4/6 inhibition in endometrial malignancies driven by PTEN deficiency, and it reveals an important role of cyclin D-CDK4/6 activity in their development., This work was supported by grants FIS PI13/00263, SAF2016-80157-R, PI13/01701, 2009SGR794,Grupos estables AECC (AECC2011), RETICS(RD12/0036/0013), Catalunya contra el cáncer, Programa de intensificación de la investigación, Instituto Carlos III, and BFU 2013-42895-P. MAD holds a predoctoral fellowship from Ministerio de Educación
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A Smad3-PTEN regulatory loop controls proliferation and apoptotic responses to TGF-β in mouse endometrium, SMAD3-PTEN crosstalk regulates TGF-β responses

  • Eritja Sánchez, Núria
  • Felip Nogués, Isidre
  • Dosil Garcia, Maria Alba
  • Vigezzi, Lucia
  • Mirantes Barbeito, Cristina
  • Yeramian Hakim, Andree
  • Navaridas Fernández de Bobadilla, Raúl
  • Santacana Espasa, Maria
  • Llobet Navàs, David
  • Yoshimura, Akihiko
  • Nomura, Masatoshi
  • Encinas Martín, Mario
  • Matias-Guiu, Xavier
  • Dolcet Roca, Xavier
The TGF-β/Smad and the PI3K/AKT signaling pathways are important regulators of proliferation and apoptosis, and their alterations lead to cancer development. TGF-β acts as a tumor suppressor in premalignant cells, but it is a tumor promoter for cancerous cells. Such dichotomous actions are dictated by different cellular contexts. Here, we have unveiled a PTEN-Smad3 regulatory loop that provides a new insight in the complex cross talk between TGF-β/Smad and PI3K/AKT signaling pathways. We demonstrate that TGF-β triggers apoptosis of wild-type polarized endometrial epithelial cells by a Smad3-dependent activation of PTEN transcription, which results in the inhibition of PI3K/AKT signaling pathway. We show that specific Smad3 knockdown or knockout reduces basal and TGF-β-induced PTEN expression in endometrial cells, resulting in a blockade of TGF-β-induced apoptosis and an enhancement of cell proliferation. Likewise Smad3 deletion, PTEN knockout prevents TGF-β-induced apoptosis and increases cell proliferation by increasing PI3K/AKT/mTOR signaling. In summary, our results demonstrate that Smad3-PTEN signaling axis determine cellular responses to TGF-β., Supported by grants SAF2016-80157-R from Ministerio de Economía y Competitividad, PI13/00263 and PI13/01701 from Fondo de Investigaciones Sanitarias del Instituto de Salud Carlos III cofinanciado por Fondo Europeo de Desarrollo Regional (FEDER) (“Una manera de hacer Europa”), Red Temática de investigación en Cáncer RD12/0036/0013 and Red de Oncología (CIBERONC). Grups consolidats de la Generalitat de Catalunya (2009SGR794), Fundació La Marató de TV3, Grupos estables AECC, Catalunya contra el cáncer and programa de intensificación de la investigación, Instituto Carlos III.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Endometrial PTEN Deficiency Leads to SMAD2/3 Nuclear Translocation

  • Eritja Sánchez, Núria
  • Navaridas Fernández de Bobadilla, Raúl
  • Ruiz Mitjana, Anna
  • Vidal Sabanés, Maria
  • Egea Navarro, Joaquim
  • Encinas Martín, Mario
  • Matias-Guiu, Xavier
  • Dolcet Roca, Xavier
TGF-β has a dichotomous function, acting as tumor suppressor in premalignant cells but as a tumor promoter for cancerous cells. These contradictory functions of TGF-β are caused by different cellular contexts, including both intracellular and environmental determinants. The TGF-β/SMAD and the PI3K/PTEN/AKT signal transduction pathways have an important role in the regulation of epithelial cell homeostasis and perturbations in either of these two pathways' contributions to endometrial carcinogenesis. We have previously demonstrated that both PTEN and SMAD2/3 display tumor-suppressive functions in the endometrium, and genetic ablation of either gene results in sustained activation of PI3K/AKT signaling that suppresses TGF-β-induced apoptosis and enhances cell proliferation of mouse endometrial cells. However, the molecular and cellular effects of PTEN deficiency on TGF-β/SMAD2/3 signaling remain controversial. Here, using an in vitro and in vivo model of endometrial carcinogenesis, we have demonstrated that loss of PTEN leads to a constitutive SMAD2/3 nuclear translocation. To ascertain the function of nuclear SMAD2/3 downstream of PTEN deficiency, we analyzed the effects of double deletion PTEN and SMAD2/3 in mouse endometrial organoids. Double PTEN/SMAD2/3 ablation results in a further increase of cell proliferation and enlarged endometrial organoids compared to those harboring single PTEN, suggesting that nuclear translocation of SMAD2/3 constrains tumorigenesis induced by PTEN deficiency., This research was supported by grants SAF2016-80157-R and PID2019-104734RB-I00 from Spanish Ministerio de Ciencia, Innovación y Universidades, Grupos estables de la Asociación Española Contra el Cancer, AECC
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

ENDOG Impacts on Tumor Cell Proliferation and Tumor Prognosis in the Context of PI3K/PTEN Pathway Status

  • Barés Junqué, Gisel
  • Beà Tàrrega, Aida
  • Hernández, Luís
  • Navaridas Fernández de Bobadilla, Raúl
  • Felip Nogués, Isidre
  • Megino-Luque, Cristina
  • Blasco Angulo, Natividad
  • Nadeu, Ferran
  • Campo, Elías
  • Llovera i Tomàs, Marta
  • Dolcet Roca, Xavier
  • Sanchis, Daniel
EndoG influences mitochondrial DNA replication and is involved in somatic cell proliferation. Here, we investigated the effect of ENDOG/Endog expression on proliferation in different tumor models. Noteworthy, ENDOG deficiency reduced proliferation of endometrial tumor cells expressing low PTEN/high p-AKT levels, and Endog deletion blunted the growth of PTEN-deficient 3D endometrial cultures. Furthermore, ENDOG silencing reduced proliferation of follicular thyroid carcinoma and glioblastoma cell lines with high p-AKT expression. High ENDOG expression was associated with a short time to treatment in a cohort of patients with chronic lymphocytic leukemia (CLL), a B-cell lymphoid neoplasm with activation of PI3K/AKT. This clinical impact was observed in the less aggressive CLL subtype with mutated IGHV in which high ENDOG and low PTEN levels were associated with worse outcome. In summary, our results show that reducing ENDOG expression hinders growth of some tumors characterized by low PTEN activity and high p-AKT expression and that ENDOG has prognostic value for some cancer types., This research was funded by Ministerio de Ciencia, Innovación y Universidades, Gobierno de España, grant numbers SAF2013-44942-R and PID2019-104509RB-I00 to D.S.; grant numbers SAF2016-80157-R and PID2019-104734RB-I00 to X.D.; Fundació La Marató TV3, grant number 20153810 to D.S. G.B. holds a contract from the University of Lleida; A.B. holds a contract from Fundació La Marató TV3 and IRBLleida/Diputació de Lleida; The Spanish Ministry of Science and Innovation (MICINN) through the Instituto de Salud Carlos III (ISCIII) International Cancer Genome Consortium for Chronic Lymphocytic Leukemia (ICGC-CLL Genome Project) to E.C.. Fundació La Marato de TV3 (201920-30) to L.H. Support Groups de Recerca AGAUR 2014-SGR-795 of the Generalitat de Catalunya to E.C.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Involvement of the mitochondrial nuclease EndoG in the regulation of cell proliferation through the control of reactive oxygen species

  • Blasco Angulo, Natividad
  • Beà Tàrrega, Aida
  • Barés Junqué, Gisel
  • Girón, Cristina
  • Navaridas Fernández de Bobadilla, Raúl
  • Irazoki, Andrea
  • López-Lluch, Guillermo
  • Zorzano, Antonio
  • Dolcet Roca, Xavier
  • Llovera i Tomàs, Marta
  • Sanchis, Daniel
The apoptotic nuclease EndoG is involved in mitochondrial DNA replication. Previous results suggested that, in addition to regulate cardiomyocyte hypertrophy, EndoG could be involved in cell proliferation. Here, by using in vivo and cell culture models, we investigated the role of EndoG in cell proliferation. Genetic deletion of Endog both in vivo and in cultured cells or Endog silencing in vitro induced a defect in rodent and human cell proliferation with a tendency of cells to accumulate in the G1 phase of cell cycle and increased reactive oxygen species (ROS) production. The defect in cell proliferation occurred with a decrease in the activity of the AKT/PKB-GSK-3β-Cyclin D axis and was reversed by addition of ROS scavengers. EndoG deficiency did not affect the expression of ROS detoxifying enzymes, nor the expression of the electron transport chain complexes and oxygen consumption rate. Addition of the micropeptide Humanin to EndoG-deficient cells restored AKT phosphorylation and proliferation without lowering ROS levels. Thus, our results show that EndoG is important for cell proliferation through the control of ROS and that Humanin can restore cell division in EndoG-deficient cells and counteracts the effects of ROS on AKT phosphorylation., This research was funded by Ministerio de Ciencia e Innovación, Gobierno de España, grant numbers SAF2013-44942-R and PID2019-104509RB-I00 to D.S. and SAF2016-80157-R to X.D.; Fundació La Marató, Catalunya, grant number 20153810 to D.S.; AGAUR, Generalitat de Catalunya, Catalunya, grant number 2014-SGR-1609 to D.S. G.B. holds a contract from the University of Lleida; A.B. contract has been funded by Fundació La Marató TV3 and Diputació de Lleida/IRBLleida.